Core Insights - Charles River Laboratories (CRL) reported a revenue of 1billionforthequarterendedDecember2024,reflectingadecreaseof1.12.66 from 2.46inthepreviousyear[1]−TherevenueexceededtheZacksConsensusEstimateof975.34 million by 2.79%, and the EPS also surpassed the consensus estimate of 2.50by6.40204.26 million, exceeding the average estimate of 201.13millionbyanalysts,withayear−over−yearincreaseof4.3603.35 million, below the average estimate of 566.67million,showingadeclineof3.6194.94 million, slightly below the average estimate of 205.81million,withayear−over−yearincreaseof1.6811.91 million, surpassing the average estimate of 795.10million,butreflectingayear−over−yeardeclineof3.1190.64 million, exceeding the average estimate of 177.81million,withanincreaseof8.646.54 million, slightly above the average estimate of 45.01million[4]−Non−GAAPoperatingincomeforDiscoveryandSafetyAssessmentwas148.98 million, exceeding the average estimate of 132.62million[4]−Non−GAAPoperatingincomeforManufacturingSolutionswas55.91 million, below the average estimate of 58.54million[4]−UnallocatedCorporateOverheadreportedanoperatinglossof61.76 million, worse than the average estimate of -43.28million[4]−OperatingincomeforResearchModelsandServiceswas13.77 million, significantly below the average estimate of 27.04million[4]−OperatingincomeforDiscoveryandSafetyAssessmentwas62.86 million, falling short of the average estimate of 102.93million[4]−ManufacturingSolutionsreportedanoperatinglossof182.55 million, compared to the average estimate of a profit of $44.27 million [4] Stock Performance - Over the past month, shares of Charles River have declined by 9.1%, contrasting with a 4.7% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]